China Universal Asset Management Company’s Ligand Pharmaceuticals LGND Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $441K | Buy |
3,875
+13
| +0.3% | +$1.48K | 0.04% | 247 |
|
|
2025
Q1 | $406K | Sell |
3,862
-145
| -4% | -$15.2K | 0.04% | 262 |
|
|
2024
Q4 | $429K | Buy |
4,007
+493
| +14% | +$52.8K | 0.04% | 264 |
|
|
2024
Q3 | $352K | Buy |
3,514
+1,402
| +66% | +$140K | 0.04% | 254 |
|
|
2024
Q2 | $178K | Sell |
2,112
-1,325
| -39% | -$112K | 0.03% | 255 |
|
|
2024
Q1 | $251K | Buy |
3,437
+1,425
| +71% | +$104K | 0.03% | 265 |
|
|
2023
Q4 | $144K | Buy |
2,012
+1,571
| +356% | +$112K | 0.03% | 245 |
|
|
2023
Q3 | $26.4K | Buy |
441
+215
| +95% | +$12.9K | 0.01% | 280 |
|
|
2023
Q2 | $16.3K | Sell |
226
-5
| -2% | -$361 | 0.01% | 284 |
|
|
2023
Q1 | $17K | Buy |
231
+60
| +35% | +$4.41K | 0.01% | 237 |
|
|
2022
Q4 | $11.4K | Sell |
171
-84
| -33% | -$5.61K | ﹤0.01% | 216 |
|
|
2022
Q3 | $14K | Buy |
+255
| New | +$14K | 0.01% | 179 |
|